2024 Nasdaq lpcn - Nov 3, 2022 · SALT LAKE CITY, Nov. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop ...

 
SALT LAKE CITY, June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted US patent 11,337,987 for "Compositions and Methods for Treating Central Nervous System …. Nasdaq lpcn

Lipocine Inc. (LPCN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Add to watchlist 2.6300 +0.2200 (+9.13%) At close: 04:00PM EST 1d 5d 1m 6m YTD 1y 5y Max …Mar 31, 2023 · By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 1Q:23 Financial and Operational Results Efforts year to date for Lipocine Inc. (NASDAQ:LPCN) were dominated by the pharmacokinetic (PK) study for LPCN 1154, which is in development for postpartum depression (PPD). The underlying drug in LPCN 1154 is brexanolone, which is approved in an intravenous (IV) formulation for PPD. May 20, 2022 · By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT NASH Open Label Extension Study Results On May 12, 2022 Lipocine (NASDAQ:LPCN) announced results from its NASH Open Label Extension (OLE) study. Safety was confirmed with no observed safety signals over the 72-week duration of exposure and liver injury markers were either maintained or reduced with the use of LPCN 1144. The SALT LAKE CITY, May 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results ...Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT. LPCN - Lipocine Inc ...Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products ...SALT LAKE CITY, Nov. 18, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a ...Jul 13, 2020 · SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has ... SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of ...Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products ...SALT LAKE CITY, June 14, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S ...3. Lipocine Inc. (NASDAQ:LPCN) Lipocine Inc. is a biotech penny stock that has climbed by over 6% in the past five days. This is a company that makes products for treating metabolic and endocrine disorders. Currently, it is developing LPCN 1144, which is in Phase 2 clinical trial to treat non-cirrhotic non-alcoholic steatohepatitis.18 Oct 2021 ... (NASDAQ: ATRS) (the “Company”), a specialty ... Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN ...Dec 9, 2020 · SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S ... Nov 10, 2023 · LPCN's current price target is $68.00. Learn why top analysts are making this stock forecast for Lipocine at MarketBeat. We feel now is a pretty good time to analyse Lipocine Inc.'s (NASDAQ:LPCN) business as it appears the company may be on the cusp of a considerable accomplishment. Lipocine Inc., a clinical-stage ...Lipocine Inc. Common Stock (LPCN) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.SALT LAKE CITY, June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data will be presented at The International Liver Congress™ 2021, the annual meeting of the European Association for the Study of the Liver ("EASL"), …SALT LAKE CITY, June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the ...SALT LAKE CITY, Nov. 10, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Lipocine (NASDAQ:LPCN) has had a great run on the share market with its stock up by a significant 31% over the last... Get the latest Lipocine Inc. (LPCN) stock news and …19 Apr 2020 ... Biotech companies are unique in that only a few key indicators like positive data or regulatory approvals can signal they are well on their way ...SALT LAKE CITY, May 12, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biopharmaceutical company leveraging its proprietary technology to develop innovative products to treat neuroendocrine ...Nov 9, 2022 · Third quarter Ended September 30, 2022 Financial Results. Lipocine reported a net loss of $2.4 million, or ( $0.03 ) per diluted share for the quarter ended September 30, 2022, compared with a net ... Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis. Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY, Dec. 19, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating... Nov 9, 2022.SALT LAKE CITY, Jan. 28, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of an underwritten public offering of 16,428,571 shares of its common stock, offered at a price of $1.75 to the public, which included the exercise in full by the …What is Lipocine Inc. (LPCN)'s stock price history? Over the last year, Lipocine Inc.’s stock price has decreased by 70.59%. Lipocine Inc. is currently approximately $2.51 per share.(NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that in an effort to streamline the issues and associated costs for dispute in ...SALT LAKE CITY, June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical ...0.31%. $40.52B. LPCN | Complete Lipocine Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Fintel reports that on July 27, 2023, Cantor Fitzgerald reiterated coverage of Lipocine (NASDAQ:LPCN) with a Overweight recommendation. Analyst Price Forecast Suggests 626.67% UpsideLipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States. TLANDO is an oral testosterone product for testosterone replacement …SALT LAKE CITY, Aug. 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial results for the second quarter and six months ended June 30, 2023, and provided a corporate update.SALT LAKE CITY, Nov. 6, 2020 /PRNewswire/ -- Lipocine Inc (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that it is working towards taking action on the TLANDO New Drug Application ("NDA") on …May 11, 2023 · SALT LAKE CITY, May 11, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary ... Vislink Technologies, Inc. (NASDAQ:VISL) has seen an increase in support from the world’s most elite money managers of late. ... (NASDAQ:CLGN), and Lipocine Inc (NASDAQ:LPCN). All of these ...Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products ...Lipocine Inc. Common Stock (LPCN) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.SALT LAKE CITY, June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States ...SALT LAKE CITY, May 12, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biopharmaceutical company leveraging its proprietary technology to develop innovative products to treat neuroendocrine ...8 Nov 2023 ... (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary ...All day - Lipcone's (NASDAQ:LPCN) is on watch with a potential FDA approval on Tlando following a two-month review. The FDA issued tentative approval in December of 2020. The FDA issued tentative ...Lipocine Inc. (NASDAQ:LPCN) announced positive topline 36-week results from its Phase 2 proof of concept clinical study, NCT04134091, investigating LPCN 1144 in men with biopsy-confirmed non ...Aug 16, 2023 · On August 10, 2023 Lipocine (NASDAQ: LPCN) filed its 2Q:23 Form 10-Q and posted its earnings release for the quarter ending June 30, 2023. Topline results from LPCN 1148 proof of concept trial ... Oct 23, 2023 · SALT LAKE CITY, Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will ... By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Lipocine Inc. (NASDAQ:LPCN) provided a pleasant surprise to investors with its strong Phase II results from its LPCN 1148 ...SALT LAKE CITY, Nov. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop ...SALT LAKE CITY, Jan. 4, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and end...SALT LAKE CITY, April 17, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the ...Virios Therapeutics (NASDAQ:VIRI) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and …Earnings Growth. Earnings for Lipocine are expected to grow in the coming year, from ($2.99) to ($1.84) per share. Price to Earnings Ratio vs. the Market. The P ...SALT LAKE CITY, June 14, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S ...Fiscal Q3 2023 ended 9/30/23. Get the latest Lipocine Inc (LPCN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and ... 28 Sep, 2021, 08:00 ET. SALT LAKE CITY, Sept. 28, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today ...SALT LAKE CITY, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has extended ...SALT LAKE CITY, June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States ...By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 2022 was an eventful year for Lipocine Inc (NASDAQ:LPCN) with both product and strategy achievements. The company’s first ...Lipocine Inc (NASDAQ:LPCN). 2.56. Delayed Data. As of Dec 01. +0.15 / +6.22%. Today's Change. 2.31. Today|||52-Week Range. 10.33. -62.14%. Year-to-Date. QuoteSALT LAKE CITY, Jan. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer-reviewed publication of positive Phase 3 clinical data from the Dosing Validation ("DV") study which evaluated the fixed-dose oral testosterone …Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies Stocks... LPCN 1148 in the ongoing open label extension also showed improvement in sarcopenia SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN) ...Search. Lipocine Inc. LPCN (U.S.: Nasdaq). search. View All companies. AT CLOSE 3:59 PM EST 11/30/23. $2.41 USD; -0.01 -0.41%. Volume 9,239. AFTER HOURS 7:21 PM ...Jun 30, 2022 · By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Second Quarter 2022 Financial and Operational Results On August 8, 2022 Lipocine (NASDAQ:LPCN) filed its second quarter 2022 Form 10-Q and posted its earnings release for the quarter ending June 30, 2022. Highlights for the second quarter 2022 and to-date include: New board of director appointments – April 2022 LPCN 1144 Find the latest Earnings Report Date for Lipocine Inc. Common Stock (LPCN) at Nasdaq.com.(NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that in an effort to streamline the issues and associated costs for dispute in ...NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key...Lipocine Inc (US:LPCN) has 0 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Lipocine Inc (NASDAQ:LPCN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has ...Lipocine Stock (NASDAQ:LPCN), Quotes and News Summary - Benzinga Lipocine Stock (NASDAQ: LPCN) stock price, news, charts, stock research, profile.SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has ...It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. ... Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT On May 9, 2022 Lipocine (NASDAQ:LPCN) filed its Form 10-Q and posted its earnings release for the quarter ending March 31 ...SALT LAKE CITY, Feb. 11, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that in an effort to streamline the issues and associated costs for dispute in its infringement lawsuit against Clarus Therapeutics, Inc. ("Clarus") in the United States District Court ("Delaware") related to …Dec 9, 2020 · SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S ... SALT LAKE CITY, Dec. 31, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced completion of a definitive phlebotomy study ("Phlebotomy Study") to assess the extent, if any, of clinically meaningful ex vivo conversion of testosterone undecanoate ("TU") to testosterone ("T") in serum blood …SALT LAKE CITY, March 3, 2021 - /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO™ will be presented at the ENDO 2021 Conference, to take place March 20-23, 2021.TLANDO is an oral …Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksSALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of ...2.580. 0.00%. Trade stocks. You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform. Webull offers LPCN Ent Holdg (LPCN) historical stock prices, in-depth market analysis, NASDAQ: LPCN real-time stock quote data, in-depth charts, free LPCN options chain data, and a fully built ... LPCN's current price target is $68.00. Learn why top analysts are making this stock forecast for Lipocine at MarketBeat.26 Oct, 2023, 08:00 ET. Lipocine and FDA agreed on the acceptance criteria for the pivotal study which enables advancement of LPCN 1154 for postpartum depression (PPD) Company on track to initiate ...SALT LAKE CITY, Dec. 22, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has been dosed in its Phase 2 proof-of-concept clinical study (NCT04874350) for the management of liver cirrhosis. The Phase 2 study is a ...Nasdaq lpcn

14 Nov 2023 ... SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous .... Nasdaq lpcn

nasdaq lpcn

See the latest Lipocine Inc stock price (LPCN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.SALT LAKE CITY, Nov. 1, 2023 / PRNewswire / -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract on LPCN 1148 has been selected for a late breaking oral presentation at The American Association for the Study of Liver Diseases (AASLD) – The ...Quarter Ended September 30, 2023 Financial Results. Lipocine reported a net loss of $6.7 million, or ($1.27) per diluted share, for the three months ended September 30, 2023, compared with a net ...SALT LAKE CITY, June 23, 2021 /PRNewswire/ -- Lipocine Inc. , a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data will be...Lipocine Inc. (LPCN.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Lipocine Inc. | Nasdaq: LPCN | Nasdaq.SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S ...Jul 27, 2023 · LPCN 1148 is an oral candidate under development for the clinical management of cirrhosis. ... Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ... Nov 10, 2021 · SALT LAKE CITY, Nov. 10, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial ... Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis. Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY, Dec. 19, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating... Nov 9, 2022.Le cours de l'action LIPOCINE LPCN sur Boursorama : historique de la cotation sur NASDAQ, graphique, actualités, consensus des analystes et informations ...Lipocine Inc. (NASDAQ:LPCN) posted its quarterly earnings data on Wednesday, November, 8th. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.70. The specialty pharmaceutical company had revenue of ($3.12) million for the quarter.SALT LAKE CITY, March 10, 2023 /PRNewswire/ -- Lipocine Inc. , a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board of Directors...All day - Lipcone's (NASDAQ:LPCN) is on watch with a potential FDA approval on Tlando following a two-month review. The FDA issued tentative approval in December of 2020. The FDA issued tentative ...By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT On May 9, 2022 Lipocine (NASDAQ:LPCN) filed its Form 10-Q and posted its earnings release for the quarter ending March 31 ...SALT LAKE CITY, Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract ...Oct 26, 2023 · Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR (“LPCN 1111”), LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone ... SALT LAKE CITY, Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract ...Lipocine Inc. (NASDAQ: LPCN), today announced positive topline results from a pilot clinical PK bridge study of LPCN 1154 (oral brexanolone) with a comparator, IV brexanolone. The pilot study is ...View real-time LPCN stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... Virios Therapeutics (NASDAQ:VIRI) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and …4 days ago ... One share of LPCN stock can currently be purchased for approximately $2.63. Is Lipocine Inc. listed on the NASDAQ or NYSE? Lipocine ...○ Executive catalyst in taking Lipocine (NASDAQ: LPCN) public via a reverse merger raising $52M in a PIPE and a fully underwritten follow-on offering and ...Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT. LPCN - Lipocine Inc ...Find the latest Financials data for Lipocine Inc. Common Stock (LPCN) at Nasdaq.com.Third quarter Ended September 30, 2022 Financial Results. Lipocine reported a net loss of $2.4 million, or ( $0.03 ) per diluted share for the quarter ended September 30, 2022, compared with a net ...Nov 14, 2023 · Lipocine has generated ($3.14) earnings per share over the last year ( ($3.14) diluted earnings per share). Earnings for Lipocine are expected to grow in the coming year, from ($2.19) to ($1.47) per share. Lipocine has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 8th, 2024 ... Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis. Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY, Dec. 19, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating... Nov 9, 2022.Nov 29, 2023 · Lipocine Inc. (NASDAQ:LPCN) posted its quarterly earnings data on Wednesday, November, 8th. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.70. The specialty pharmaceutical company had revenue of ($3.12) million for the quarter. Complete Lipocine Inc. stock information by Barron's. View real-time LPCN stock price and news, along with industry-best analysis.Nasdaq provides NLS Volume, Previous Close, Today's High & Low, and the 52 week High & Low. The intraday chart, the last-five real-time quotes and sales data. Real-time stock …SALT LAKE CITY, Dec. 4, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that it is continuing to work towards taking action on the TLANDO New Drug Application …SALT LAKE CITY, Nov. 6, 2020 /PRNewswire/ -- Lipocine Inc (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that it is working towards taking action on the TLANDO New Drug Application ("NDA") on …SALT LAKE CITY, Feb. 16, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that the Company and the other defendants have entered into a memorandum of understanding to settle the purported securities class action litigation captioned In re Lipocine Inc. Securities Litigation, …By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 1Q:23 Financial and Operational Results Efforts year to date for Lipocine Inc. (NASDAQ:LPCN) were dominated by the pharmacokinetic (PK) study for LPCN 1154, which is in development for postpartum depression (PPD). The underlying drug in LPCN 1154 is brexanolone, which is approved in an intravenous (IV) formulation for PPD.Mar 29, 2022 · 29 Mar, 2022, 07:05 ET. Commercial launch expected in 2Q 2022. SALT LAKE CITY, March 29, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a clinical-stage biopharmaceutical company focused on ... SALT LAKE CITY, May 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, today ...This is a decrease of 15 owner (s) or 21.74% in the last quarter. Average portfolio weight of all funds dedicated to LPCN is 0.01%, a decrease of 21.85%. Total shares owned by institutions ...Find the latest Earnings Report Date for Lipocine Inc. Common Stock (LPCN) at Nasdaq.com. Nov 30, 2022 · By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Third Quarter 2022 Financial and Operational Results On November 9, 2022 Lipocine (NASDAQ:LPCN) filed its third quarter ... By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 1Q:23 Financial and Operational Results Efforts year to date for Lipocine Inc. (NASDAQ:LPCN) were dominated by the pharmacokinetic (PK) study for LPCN 1154, which is in development for postpartum depression (PPD). The underlying drug in LPCN 1154 is brexanolone, which is approved in an intravenous (IV) formulation for PPD.SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the ...10 Mar, 2023, 08:30 ET. SALT LAKE CITY, March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today ...10 Mar, 2023, 08:30 ET. SALT LAKE CITY, March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today ...Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are ...SALT LAKE CITY, June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted US patent 11,337,987 for "Compositions and Methods for Treating Central Nervous System …Nov 8, 2023 · Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products ... SALT LAKE CITY, Nov. 18, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a ...Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products ...If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...May 16, 2023 · SALT LAKE CITY, May 16, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), today announced positive topline results from a pilot clinical PK bridge study of LPCN 1154 (oral brexanolone) with a ... May 16, 2023 · SALT LAKE CITY, May 16, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), today announced positive topline results from a pilot clinical PK bridge study of LPCN 1154 (oral brexanolone) with a ... SALT LAKE CITY, Dec. 31, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced completion of a definitive phlebotomy study ("Phlebotomy Study") to assess the extent, if any, of clinically meaningful ex vivo conversion of testosterone undecanoate ("TU") to testosterone ("T") in serum blood …LPCN's current price target is $68.00. Learn why top analysts are making this stock forecast for Lipocine at MarketBeat.Search. Lipocine Inc. LPCN (U.S.: Nasdaq). search. View All companies. AT CLOSE 3:59 PM EST 11/30/23. $2.41 USD; -0.01 -0.41%. Volume 9,239. AFTER HOURS 7:21 PM ...Nov 8, 2023 · Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products ... 26 Oct, 2023, 08:00 ET. Lipocine and FDA agreed on the acceptance criteria for the pivotal study which enables advancement of LPCN 1154 for postpartum depression (PPD) Company on track to initiate ...Sep 30, 2023 · Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis. Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY, Dec. 19, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating... Nov 9, 2022. Financial Performance. In 2022, Lipocine's revenue was $500,000, a decrease of -96.90% compared to the previous year's $16.14 million. Losses were -$10.76 million, 1595.9% more than in 2021. Financial Statements.. Lowest margin futures